Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SR 314Session 2025-2026

A Resolution designating the week of May 4 through 10, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

Printer's No. PN1712

See other bills
under the
same topic PRINTER'S NO. 1712 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE RESOLUTION No.314 Session of 2026 INTRODUCED BY COLLETT, HUGHES, HAYWOOD, TARTAGLIONE, COSTA, PHILLIPS-HILL, SANTARSIERO, CAPPELLETTI, VOGEL, KANE, PISCIOTTANO AND STREET, MAY 7, 2026 REFERRED TO RULES AND EXECUTIVE NOMINATIONS, MAY 7, 2026 A RESOLUTIONDesignating the week of May 4 through 10, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.WHEREAS, Many individuals living with serious mental illnesses, including schizophrenia and other schizoaffective disorders, bipolar disorder and major depressive disorder, require treatment with antipsychotic medications for effective management, and antipsychotic prescribing rates in the United States continue to rise; andWHEREAS, While ongoing treatment with antipsychotic medications can be necessary, prolonged use is associated with Tardive Dyskinesia (TD); andWHEREAS, TD is a movement disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs and extremities; andWHEREAS, TD can develop months, years or decades after an individual starts taking antipsychotic medications and may persist even after the individual has discontinued use of those 1234567891011121314151617 medications; andWHEREAS, Even mild symptoms of TD can be stigmatizing and impair physical, social and emotional well-being; andWHEREAS, Individuals at higher risk of TD include those over 55 years of age, Black individuals, women, individuals with mood or substance use disorders, individuals with intellectual disabilities or central nervous system injuries and those with high cumulative exposure to antipsychotic medications; andWHEREAS, It is estimated that 800,000 adults in the United States are living with TD, and approximately 60% of those individuals remain undiagnosed; andWHEREAS, The American Psychiatric Association recommends routine TD screening as part of its clinical practice guideline for the treatment of patients receiving antipsychotic medications; andWHEREAS, Treatments approved by the United States Food and Drug Administration for TD can provide options for symptom management and improved quality of life for many individuals living with TD; andWHEREAS, TD is often unrecognized and individuals living with the condition are commonly misdiagnosed, underscoring the urgency of early screening, detection and intervention; andWHEREAS, The Senate can raise awareness of TD among the public, the medical community, patients and care partners; therefore be itRESOLVED, That the Senate designate the week of May 4 through 10, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania; and be it furtherRESOLVED, That the Senate underscore the importance of early detection and intervention to improve outcomes for individuals 20260SR0314PN1712 - 2 - 123456789101112131415161718192021222324252627282930 living with mental health conditions who are prescribed antipsychotic medications, and support efforts to raise awareness about the causes and symptoms of TD and the importance of routine TD screening; and be it furtherRESOLVED, That the Senate encourage anyone experiencing uncontrollable, abnormal and repetitive movements to consult their health care provider regarding their symptoms.20260SR0314PN1712 - 3 - 1234567

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.